electroCore (ECOR) 10-Q 4 Nov 21 2021 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2021	Nov. 01, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Trading Symbol	ECOR
Entity Registrant Name	electroCore, Inc.
Entity Central Index Key	0001560258
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		70,697,680
Entity File Number	001-38538
Entity Tax Identification Number	20-3454976
Entity Address, Address Line One	200 Forge Way
Entity Address, Address Line Two	Suite 205
Entity Address, City or Town	Rockaway
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07866
City Area Code	973
Local Phone Number	290-0097
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, par value $0.001 per share
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Document Quarterly Report	true
Document Transition Report	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 37,995,008	$ 4,241,937
Marketable securities	1,001,080	18,386,160
Accounts receivable, net	329,778	270,546
Inventories, net	1,082,325	876,436
Prepaid expenses and other current assets	1,476,348	1,288,588
Total current assets	41,884,539	25,063,667
Inventories, noncurrent	4,349,009	4,865,181
Property and equipment, net	171,028	244,047
Operating lease right of use assets	539,728	517,257
Other assets, net	626,445	828,011
Total assets	47,570,749	31,518,163
Current liabilities:
Accounts payable	1,250,534	2,078,699
Accrued expenses and other current liabilities	4,429,843	2,965,702
Notes payable, current		311,354
Current portion of operating lease liabilities	58,482	534,547
Total current liabilities	5,738,859	5,890,302
Noncurrent liabilities:
Operating lease liabilities, noncurrent	715,530	885,333
Note payable, noncurrent		1,097,946
Total liabilities	6,454,389	7,873,581
Commitments and contingencies
Stockholders' equity:
Preferred Stock, par value $0.001 per share; 10,000,000 shares authorized at September 30, 2021 and December 31, 2020; 0 shares issued and outstanding at September 30, 2021 and December 31, 2020
Common Stock, par value $0.001 per share; 500,000,000 shares authorized at September 30, 2021 and December 31, 2020; 70,442,309 shares issued and outstanding at September 30, 2021 and 45,559,765 shares issued and outstanding at December 31, 2020	70,442	45,560
Additional paid-in capital	159,796,442	130,205,027
Accumulated deficit	(119,261,417)	(106,990,148)
Accumulated other comprehensive loss	(124,717)	(251,467)
Total stockholders' equity	40,480,750	23,008,972
Noncontrolling interest	635,610	635,610
Total equity	41,116,360	23,644,582
Total liabilities and equity	$ 47,570,749	$ 31,518,163

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	70,442,309	45,559,765
Common stock, shares outstanding	70,442,309	45,559,765

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
Net sales	$ 1,487,093	$ 1,080,841	$ 3,960,401	$ 2,567,567
Cost of goods sold	355,046	347,504	1,093,304	918,605
Gross profit	1,132,047	733,337	2,867,097	1,648,962
Operating expenses
Research and development	470,275	629,002	1,794,146	3,182,646
Selling, general and administrative	4,646,815	4,592,936	15,644,324	16,426,991
Restructuring and other severance related charges				464,606
Total operating expenses	5,117,090	5,221,938	17,438,470	20,074,243
Loss from operations	(3,985,043)	(4,488,601)	(14,571,373)	(18,425,281)
Other (income) expense
Gain on extinguishment of debt			1,422,214
Interest and other income	3,834	5,719	8,493	80,460
Other expense	3,771	3,522	7,293	13,350
Total other (income) expense	63	2,197	1,423,414	67,110
Loss before income taxes	(3,984,980)	(4,486,404)	(13,147,959)	(18,358,171)
(Provision) benefit from income taxes	(8,705)		876,690	1,170,890
Net loss	$ (3,993,685)	$ (4,486,404)	$ (12,271,269)	$ (17,187,281)
Net loss per share of common stock - Basic and Diluted (see Note 12)	$ (0.06)	$ (0.10)	$ (0.22)	$ (0.47)
Weighted average common shares outstanding - Basic and Diluted (see Note 12)	69,511,498	44,030,685	55,308,381	36,847,548

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (3,993,685)	$ (4,486,404)	$ (12,271,269)	$ (17,187,281)
Other comprehensive (loss) income:
Foreign currency translation adjustment	(22,282)	(81,602)	124,366	(145,617)
Unrealized gain (loss) on securities, net of taxes as applicable	27	(2,210)	2,384	(3,443)
Other comprehensive (loss) income	(22,255)	(83,812)	126,750	(149,060)
Comprehensive loss	$ (4,015,940)	$ (4,570,216)	$ (12,144,519)	$ (17,336,341)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Equity - USD ($)		Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive income (loss)	Total Electrocore,Inc. Stockholders' Equity	Noncontrolling interest
Balances, beginning of period at Dec. 31, 2019		$ 24,897,118	$ 29,835	$ 107,752,066	$ (83,479,098)	$ (41,295)	$ 24,261,508	$ 635,610
Balances, beginning of period, shares at Dec. 31, 2019			29,835,183
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(7,959,349)			(7,959,349)		(7,959,349)
Other comprehensive income		51,148				51,148	51,148
Equity financing commitment fee	[1]		$ 462	(462)
Equity financing commitment fee, shares	[1]		461,676
Issuance of stock related to employee compensation plans, net of forfeitures			$ 125	(125)
Issuance of stock related to employee compensation plans, net of forfeitures, shares			124,568
Stock based compensation		744,865		744,865			744,865
Balances, end of period at Mar. 31, 2020		17,733,782	$ 30,422	108,496,344	(91,438,447)	9,853	17,098,172	635,610
Balances, end of period, shares at Mar. 31, 2020			30,421,427
Balances, beginning of period at Dec. 31, 2019		24,897,118	$ 29,835	107,752,066	(83,479,098)	(41,295)	24,261,508	635,610
Balances, beginning of period, shares at Dec. 31, 2019			29,835,183
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(17,187,281)
Balances, end of period at Sep. 30, 2020		28,896,026	$ 45,199	129,071,951	(100,666,379)	(190,355)	28,260,416	635,610
Balances, end of period, shares at Sep. 30, 2020			45,199,088
Balances, beginning of period at Dec. 31, 2019		24,897,118	$ 29,835	107,752,066	(83,479,098)	(41,295)	24,261,508	635,610
Balances, beginning of period, shares at Dec. 31, 2019			29,835,183
Balances, end of period at Dec. 31, 2020		23,644,582	$ 45,560	130,205,027	(106,990,148)	(251,467)	23,008,972	635,610
Balances, end of period, shares at Dec. 31, 2020			45,559,765
Balances, beginning of period at Mar. 31, 2020		17,733,782	$ 30,422	108,496,344	(91,438,447)	9,853	17,098,172	635,610
Balances, beginning of period, shares at Mar. 31, 2020			30,421,427
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(4,741,528)			(4,741,528)		(4,741,528)
Other comprehensive income		(116,396)				(116,396)	(116,396)
Issuance of stock		7,831,535	$ 8,028	7,823,507			7,831,535
Issuance of stock, Shares			8,028,372
Equity financing commitment fee	[1]		$ 181	(181)
Equity financing commitment fee, shares	[1]		181,273
Issuance of stock related to employee compensation plans, net of forfeitures			$ 184	(184)
Issuance of stock related to employee compensation plans, net of forfeitures, shares			184,073
Stock based compensation		1,002,758		1,002,758			1,002,758
Financing fees		(167,299)		(167,299)			(167,299)
Balances, end of period at Jun. 30, 2020		21,542,852	$ 38,815	117,154,945	(96,179,975)	(106,543)	20,907,242	635,610
Balances, end of period, shares at Jun. 30, 2020			38,815,145
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(4,486,404)			(4,486,404)		(4,486,404)
Other comprehensive income		(83,812)				(83,812)	(83,812)
Issuance of stock		11,203,661	$ 6,080	11,197,581			11,203,661
Issuance of stock, Shares			6,079,676
Equity financing commitment fee	[1]		$ 49	(49)
Equity financing commitment fee, shares	[1]		49,565
Issuance of stock related to employee compensation plans, net of forfeitures			$ 255	(255)
Issuance of stock related to employee compensation plans, net of forfeitures, shares			254,702
Stock based compensation		742,928		742,928			742,928
Financing fees		(23,199)		(23,199)			(23,199)
Balances, end of period at Sep. 30, 2020		28,896,026	$ 45,199	129,071,951	(100,666,379)	(190,355)	28,260,416	635,610
Balances, end of period, shares at Sep. 30, 2020			45,199,088
Balances, beginning of period at Dec. 31, 2020		23,644,582	$ 45,560	130,205,027	(106,990,148)	(251,467)	23,008,972	635,610
Balances, beginning of period, shares at Dec. 31, 2020			45,559,765
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(5,383,832)			(5,383,832)		(5,383,832)
Other comprehensive income		144,144				144,144	144,144
Issuance of stock		6,920,350	$ 2,750	6,917,600			6,920,350
Issuance of stock, Shares			2,750,000
Issuance of stock related to employee compensation plans, net of forfeitures			$ 18	(18)
Issuance of stock related to employee compensation plans, net of forfeitures, shares			17,599
Settlement of accrued bonus		399,997	$ 165	399,832			399,997
Settlement of accrued bonus, shares			165,413
Stock based compensation		942,183		942,183			942,183
Balances, end of period at Mar. 31, 2021		26,667,424	$ 48,493	138,464,624	(112,373,980)	(107,323)	26,031,814	635,610
Balances, end of period, shares at Mar. 31, 2021			48,492,777
Balances, beginning of period at Dec. 31, 2020		23,644,582	$ 45,560	130,205,027	(106,990,148)	(251,467)	23,008,972	635,610
Balances, beginning of period, shares at Dec. 31, 2020			45,559,765
Balances, end of period at Sep. 30, 2021		41,116,360	$ 70,442	159,796,442	(119,261,417)	(124,717)	40,480,750	635,610
Balances, end of period, shares at Sep. 30, 2021			70,442,309
Balances, beginning of period at Mar. 31, 2021		26,667,424	$ 48,493	138,464,624	(112,373,980)	(107,323)	26,031,814	635,610
Balances, beginning of period, shares at Mar. 31, 2021			48,492,777
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(2,893,752)					(2,893,752)
Other comprehensive income		4,861				4,861	4,861
Issuance of stock related to employee compensation plans, net of forfeitures			$ 197	(197)
Issuance of stock related to employee compensation plans, net of forfeitures, shares			197,647
Stock based compensation		837,973		837,973			837,973
Balances, end of period at Jun. 30, 2021		24,616,506	$ 48,690	139,302,400	(115,267,732)	(102,462)	23,980,896	635,610
Balances, end of period, shares at Jun. 30, 2021			48,690,424
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(3,993,685)			(3,993,685)		(3,993,685)
Other comprehensive income		(22,255)				(22,255)	(22,255)
Issuance of stock		18,764,882	$ 20,700	18,744,182			18,764,882
Issuance of stock, Shares			20,700,000
Issuance of stock related to employee compensation plans, net of forfeitures			$ 100	(100)
Issuance of stock related to employee compensation plans, net of forfeitures, shares			99,505
Stock based compensation		760,437		760,437			760,437
Issuance of stock to satisfy legal fee obligation		990,475	$ 952	989,523			990,475
Issuance of stock to satisfy legal fee obligation, shares			952,380
Balances, end of period at Sep. 30, 2021		$ 41,116,360	$ 70,442	$ 159,796,442	$ (119,261,417)	$ (124,717)	$ 40,480,750	$ 635,610
Balances, end of period, shares at Sep. 30, 2021			70,442,309
[1]	Reflects commitment shares issued in accordance with the Company's equity facility purchase agreement with Lincoln Park. For additional information see Note 11 . Lincoln Park Stock Purchase Agreement.

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities:
Net loss	$ (12,271,269)	$ (17,187,281)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	2,540,593	2,490,551
Depreciation and amortization	286,448	288,589
Amortization of marketable securities discount	141,159	23,422
Gain on extinguishment of debt	(1,422,214)
Gain on legal fee obligation settled with stock	(9,525)	156,434
Net noncash lease expense	56,151	273,070
Inventory reserve charge	39,478
Other		14,893
Changes in operating assets and liabilities:
Accounts receivable, net	(59,232)	320,186
Inventories	270,805	(15,922)
Prepaid expenses and other current assets	703,257	561,248
Accounts payable	171,835	(1,631,839)
Accrued expenses and other current liabilities	324,316	(1,407,813)
Right of use operating leases	(78,622)
Operating lease liabilities	33,277	(355,274)
Net cash used in operating activities	(9,273,543)	(16,469,736)
Cash flows from investing activities:
Purchase of marketable securities	(5,082,730)	(22,166,376)
Proceeds from maturities of marketable securities	22,300,000	10,500,000
Net cash provided by (used in) investing activities	17,217,270	(11,666,376)
Cash flows from financing activities:
Shares issued net of related expenses	25,685,232	17,139,563
Proceeds from note issued		1,410,524
Net cash provided by financing activities	25,685,232	18,550,087
Effect of changes in exchange rates on cash and cash equivalents	124,112	(145,312)
Net increase in cash and cash equivalents	33,753,071	(9,731,337)
Cash and cash equivalents – beginning of period	4,241,937	13,563,791
Cash and cash equivalents – end of period	37,995,008	3,832,454
Supplemental cash flows disclosures:
Proceeds from sale of state net operating losses	1,425,935	1,170,890
Interest paid	4,649	9,366
Income taxes paid	38,622	3,254
Supplemental schedule of noncash activity:
2020 Accrued bonus awarded in equity	399,997
Accounts payable paid through issuance of common stock	$ 1,000,000	$ 1,548,702

The Company

The Company	9 Months Ended
	Sep. 30, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
The Company	Note 1. The Company electroCore, Inc. (“electroCore” or the “Company”) is a medical device company, engaged in the commercialization and development of a platform non-invasive Vagus Nerve Stimulation (“ nVNS”) therapy that can be self-administered by patients. electroCore was founded in 2005 and has primarily focused on primary headache conditions (migraine and cluster headache). electroCore, headquartered in New Jersey, has two wholly owned subsidiaries: electroCore Germany GmbH, and electroCore UK Ltd. The Company has ceased its operations in Germany, although sales to Germany are still supported by electroCore UK Ltd.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 . Summary of Significant Accounting Policies (a) Basis of Presentation The accompanying condensed consolidated financial statements were prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) and with instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934, as amended. In the opinion of management, the Company has made all necessary adjustments, which include normal recurring adjustments necessary for a fair presentation of the Company’s condensed consolidated financial position and results of operations for the interim periods presented. Certain information and disclosures normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes for the year ended included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 11, 2021 . The results for the three and nine months ended September 30, 2021 are not necessarily indicative of the results to be expected for a full year, any other interim periods or any future year or period. (b) Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of electroCore and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation. (c) Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include allowances for doubtful accounts, trade credits, rebates, co-payment assistance and sales returns, valuation of inventory , stock compensation, and contingencies. (d) Revision of Statement of Cash Flows Activity In preparation of its financial statements for the quarter ended March 31, 2021, the Company realized that proceeds from its July 1, 2020 Commercial Insurance Premium Finance and Security Agreement should have been treated as a noncash activity instead of grossed up on the accompanying condensed consolidated statement of cash flows. Even though the amount was not considered material, the financial statements have been revised. As a result, cash used in operating and cash provided by financing activities for the nine months ended September 30, 2020, decreased by approximately $600,000. (e) Reclassification of Statement of Cash Flows Activity Certain prior period amounts have been reclassified to conform to current period presentation. The reclassifications did not have an impact on net loss as previously reported.

Significant Risks and Uncertain

Significant Risks and Uncertainties	9 Months Ended
	Sep. 30, 2021
Risks And Uncertainties [Abstract]
Significant Risks and Uncertainties	Note 3 . Significant Risks and Uncertainties Liquidity The Company has experienced significant net losses, and it expects to continue to incur net losses for the near future as it works to increase market acceptance of its gammaCore therapy for the acute treatment of episodic cluster headache (“eCH”), the prevention of cluster headache in adults, and the preventive and acute treatment of migraine in adults and adolescents. The Company has never been profitable and has incurred net losses in each year since its inception. The Company incurred net losses of $12.3 million and $17.2 million for the nine months ended September 30, 2021 and 2020 The Company’s expected cash requirements for the next 12 months and beyond are largely based on the commercial success of its products. There are significant risks and uncertainties as to its ability to achieve these operating results, including as a result of the adverse impact on its headache business from the ongoing COVID-19 pandemic. The Company has historically funded its operations from the sale of its common stock. During the nine months ended September 30, 2021, the Company received net proceeds of approximately $25.7 million from such sales and as of September 30, 2021, the Company’s cash, cash equivalents and marketable securities totaled $39.0 million. The Company believes that the substantial doubt of its ability to continue as a going concern is alleviated based on proceeds received from its common stock offerings. The Company believes its cash and marketable securities will enable it to fund its operating expenses and capital expenditure requirements, as currently planned, for at least the next 12 months from the date the accompanying financial statements are issued. Concentration of Revenue Risks The Company earns a significant amount of its revenue (i) in the United States from the Department of Veterans Affairs and Department of Defense pursuant to its qualifying contract under the Federal Supply Schedule and open market sales to individual Department of Veterans Affairs facilities and (ii) in the United Kingdom from the National Health Service. Each o Three months ended September 30, Nine months ended September 30, 2021 2020 2021 2020 Revenue channel: Department of Veterans Affairs and Department of Defense 63.6 59.8 60.7 59.0 National Health Service 24.1 24.2 25.6% 28.1% During the three September 30, 2021 five specific VA/DoD facilities represented approximately 53.9% and 58.6% of the Company’s revenue from this channel, and two facilities accounted for more than 10% individually, respectively. During the nine months ended September 30, 2021 and and specific VA/DoD facilities represented approximately % and % of the Company’s revenue from this channel, and facilities accounted for more than 10% individually Foreign Currency Exchange The Company has foreign currency exchange risk related to revenue and operating expenses in currencies other than the local currencies in which it operates. The Company is exposed to currency risk from the potential changes in functional currency values of its assets, liabilities, and cash flows denominated in foreign currencies COVID- 19 The Company continues to monitor the impact of the coronavirus coronavirus coronavirus COVID-19 has significantly adversely impacted global economic activity and has contributed to significant volatility and negative pressure in financial markets. Depending upon the duration and severity of the pandemic, the continuing effect on the Company's results and outlook over the long term remains uncertain.

Revenue Recognition

Revenue Recognition	9 Months Ended
	Sep. 30, 2021
Revenue From Contract With Customer [Abstract]
Revenue Recognition	Note 4 . Revenue Recognition Geographical Net Sales The following table presents net sales disaggregated by geographic area: Three months ended September 30, Nine months ended September 30, 2021 2020 2021 2020 Geographic Market United States $ 1,103,604 $ 800,767 $ 2,810,152 $ 1,759,477 United Kingdom 366,966 278,340 1,037,908 801,055 Other 16,523 1,734 112,341 7,035 Total Net Sales $ 1,487,093 $ 1,080,841 $ 3,960,401 $ 2,567,567 Performance Obligations Revenue, net of discounts, vouchers, rebates, returns, and co-payment assistance is solely generated from the sales of the gammaCore products. Revenue is recognized when delivery of the product is completed. The Company deems control to have transferred upon the completion of delivery because that is the point in which (1) it has a present right to payment for the product, (2) it has transferred the physical possession of the product, (3) the customer has legal title to the product, (4) the customer has risks and rewards of ownership and (5) the customer has accepted the product. After the products have been delivered and control has transferred, the Company has no remaining unsatisfied performance obligations. Revenue is measured based on the consideration that the Company expects to receive in exchange for gammaCore, which represents the transaction price. The transaction price includes the fixed per-unit price of the product and variable consideration in the form of trade credits, rebates, and co-payment assistance. The per-unit price is based on the Company’s established wholesale acquisition cost less a contractually agreed upon distributor discount with the customer. Trade credits are discounts that are contingent upon a timely remittance of payment and are estimated based on historical experience. For the three and nine months ended September 30, 2021 and 2020, trade credits and discounts were immaterial. Reimbursement for co-payments made by patients under the co-payment assistance program is considered variable consideration. Effective March 1, 2020, the amount of monthly co-payment assistance was reduced to a maximum of $100 per prescription. For the three and nine months ended September 30, 2021 and 2020, net sales reflect a reduction for the reduced cost of therapy under the co-payment assistance program. The calculation of the accrual is based on an estimate of claims and the cost per claim that the Company expects to incur associated with inventory that exists in the distribution channel at period end. Managed care rebates represent our estimated obligations to pharmacy benefit managers. Rebate accruals are recognized in the same period the related revenue is recognized. Gross to net accruals based on estimated rebates were determined to be de minimis. Contract Balances The Company generally invoices the customer and recognizes revenue once its performance obligations are satisfied, at which point payment is unconditional. Accordingly, under ASC 606, the Company’s contracts with customers did not give rise to contract assets or liabilities during the three and nine months ended September 30, 2021 and 2020. Agreed upon payment terms with customers are within 120 days of shipment. Accordingly, contracts with customers do not include a significant financing component.

Cash, Cash Equivalents and Mark

Cash, Cash Equivalents and Marketable Securities	9 Months Ended
	Sep. 30, 2021
Investments Debt And Equity Securities [Abstract]
Cash, Cash Equivalents and Marketable Securities	Note 5 . Cash, Cash Equivalents and Marketable Securities The following tables summarize the Company’s cash, cash equivalents and marketable securities as of and December 31, 2020 . As of Amortized Cost Unrealized Gain Unrealized (Loss) Fair Value Cash and cash equivalents $ 37,995,008 $ — $ — $ 37,995,008 Marketable securities: U.S. Treasury Bonds 1,001,506 — (426 ) 1,001,080 Total cash, cash equivalents, and marketable securities $ 38,996,514 $ — $ (426 ) $ 38,996,088 A s of December 31, 2020 Amortized Cost Unrealized Gain Unrealized (Loss) Fair Value Cash and cash equivalents $ 4,241,937 $ — $ — $ 4,241,937 Marketable securities: U.S. Treasury Bonds 18,388,970 — (2,810 ) 18,386,160 Total cash, cash equivalents, and marketable securities $ 22,630,907 $ — $ (2,810 ) $ 22,628,097

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 6 . Fair Value Measurements Financial assets and liabilities carried at fair value are classified and disclosed in one of the following three levels of the fair value hierarchy: • Level 1—Quoted prices in active markets for identical assets or liabilities. • Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. • Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. A summary of the assets and liabilities carried at fair value in accordance with the hierarchy d efined above is as follows: Fair Value Hierarchy September 30, 2021 Total Level 1 Level 2 Level 3 Assets Cash and cash equivalents $ 37,995,008 $ 37,995,008 $ — $ — Marketable Securities: U.S. treasury bonds 1,001,080 1,001,080 — — Total $ 38,996,088 $ 38,996,088 $ — $ — Fair Value Hierarchy December 31, 2020 Total Level 1 Level 2 Level 3 Assets Cash and cash equivalents $ 4,241,937 $ 4,241,937 $ — $ — Marketable Securities: U.S. treasury bonds 18,386,160 18,386,160 — — Total $ 22,628,097 $ 22,628,097 $ — $ — The Company recognizes transfers between levels of the fair value hierarchy as of the end of the reporting period. There were no transfers within the hierarchy during the nine and year ended December 31, 2020. The carrying amount of the Company’s receivables and payables approximate their fair values due to their short maturities.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2021
Inventory Disclosure [Abstract]
Inventories	Note 7 . Inventories As of and , inventories consisted of the following: September 30, 2021 December 31, 2020 Raw materials $ 820,227 $ 1,008,653 Work in process 4,163,251 4,304,415 Finished goods 447,856 428,549 Total inventories, net 5,431,334 5,741,617 Less: noncurrent inventories 4,349,009 4,865,181 Current inventories, net $ 1,082,325 $ 876,436 The reserve for obsolete invent ory was $760,940 and as September 30, 2021 and respectively. The Company records charges for obsolete inventory in cost of goods sold. As of September 30, 2021 and December 31, 2020, noncurrent inventory was comprised of approximately $1.1 million $3.2 million

Leases

Leases	9 Months Ended
	Sep. 30, 2021
Leases [Abstract]
Leases	Note 8. Leases For the three and nine months ended September 30, 2021, the Company recognized lease expense of $52,351 and $139,597, respectively, and $149,731 and $422,765 for the three and nine months ended September 30, 2020, respectively. This expense does not include non- lease co On September 27, 2021, the Company entered into the Termination and Settlement Agreement ("Agreement") with the lessor associated with its former headquarters located in Basking Ridge, NJ. The Agreement provided for the immediate termination of the Basking Ridge lease in its entirety. In consideration for the lease termination, the Company agreed to pay the lessor a total of $500,000 in cash and issue to the lessor 200,000 shares of its common stock. As of September 30, 2021, the Company paid a total of $398,523 in cash to the lessor and accrued approximately $320,000 for the Company's remaining obligation under the Agreement. On October 4, 2021, the 200,000 shares of stock were issued to the lessor. On October 5, 2021, the Company paid to the lessor the remaining cash payment of $101,477. The tables below provide the details of the right of use assets and lease liabilities as of September 30, 2021 and December 31, 2020: September 30, 2021 December 31, 2020 Operating leases: Operating lease right of use assets $ 539,728 $ 517,257 Operating lease liabilities: Current portion of operating lease liabilities 58,482 534,547 Noncurrent operating lease liabilities 715,530 885,333 Total operating lease liabilities $ 774,012 $ 1,419,880 Weighted average remaining lease term (in years) 7.3 5.7 Weighted average discount rate 13.8 % 13.8 % Future minimum lease payments under non-cancellable operating leases as of : Remainder of 2021 $ 39,414 2022 160,486 2023 163,962 2024 167,524 2025 and thereafter 704,900 Total future minimum lease payments 1,236,286 Less: Amounts representing interest (462,274 ) Total $ 774,012

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	9 Months Ended
	Sep. 30, 2021
Payables And Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	Note 9 . Accrued Expenses and Other Current Liabilities Accrued expenses as of and consisted of the following: September 30, 2021 December 31, 2020 Accrued professional fees $ 166,050 $ 270,543 Accrued bonuses 1,400,403 1,424,878 Accrued insurance expense 873,592 164,832 Other employee related expenses 425,067 371,033 Accrued state taxes 548,705 — Lease settlement liability 320,000 — Other 696,026 734,416 $ 4,429,843 $ 2,965,702 Finance and Security Agreements On July 2, 2021, the Company entered into a Commercial Insurance Premium Finance and Security Agreement ("the Agreement"). The 2021 Agreement provides for a single borrowing by the Company of $ 1.2 million, with a ten -month term and an annual interest rate of 1.55 %. The proceeds from this transaction were used to partially fund the premiums due under certain of the Company's insurance policies. The amounts payable are secured by the Company's rights under such policies. The Company began to pay monthly installments of approximately $ 124,800 in July 2021. As of September 30, 2021, the remaining balance under the Agreement is $ 873,592 and during the three and nine months ended September 30, 2021, the Company recognized $ 2,646 in interest expense. On July 1, 2020, the Company entered into a Commercial Insurance Premium Finance and Security Agreement (“the 2020 2020 1.2 million, with a seven -month term and an annual interest rate of 2.18 %. The proceeds from this transaction were used to partially fund the premiums due under certain of the Company’s insurance policies. All borrowings related to the 2020

Note Payable

Note Payable	9 Months Ended
	Sep. 30, 2021
Notes Payable [Abstract]
Note Payable	Note 10. Notes Payable Loan Under the PPP On May 4, 2020, the Company received proceeds of $ 1.4 On May 18, 2021 , the Company received notification from the Lender of SBA's approval of the Company's application for loan forgiveness. Accordingly, the Company is not required to repay the loan. The Company has recorded the loan forgiveness as a gain in the accompanying Condensed Consolidated Statements of Operations for the nine months ended September 30, 2021 under the caption Gain on extinguishment of debt.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2021
Stockholders Equity Note [Abstract]
Stockholders' Equity	Note 11. Stockholders’ Equity Public Offering of Common Stock On July 2, 2021, the Company completed a public offering of 20,700,000 shares of its common stock at a purchase price of $1.00 per share. The net proceeds of the offering to the Company were approximately $18.8 million, after deducting the underwriting discounts, commissions, and other offering expenses. The Company intends to use the net proceeds of the offering for sales and marketing, working capital, and general corporate purposes. While the Company has no current agreements or commitments for any specific acquisitions, in-licenses or investments at this time, it may use a portion of the net proceeds for these purposes. Other Securities Purchase Agreements On August 30, 2021, the Company entered into a Securities Purchase Agreement with its legal counsel pursuant to which the Company issued 952,380 shares of common stock, at a purchase price of $1.05 per share. Upon issuance of the shares, certain of the Company's outstanding financial obligations to its legal counsel were deemed paid and satisfied in full. Lincoln Park Purchase Agreement On March 27, 2020, the Company and Lincoln Park Capital Fund, LLC ("Lincoln Park") entered into an equity facility purchase agreement ("Purchase Agreement") pursuant to which the Company had the right to sell to Lincoln Park shares of its common stock having an aggregate value of up to $25,000,000, subject to certain limitations and conditions set forth in the Purchase Agreement. Upon entering into the Purchase Agreement, the Company issued an aggregate of shares of common stock to Lincoln Park as a commitment fee. The fair value of these shares on the date of issuance was approximately $ . During 2020, the Company issued an additional shares of common stock to Lincoln Park as a further commitment fee based on the first $ of shares of common stock issued to Lincoln Park under the Purchase Agreement as Purchase Shares (as such term is defined in the Purchase Agreement). T he Company did not receive any cash proceeds from the issuance of any of the foregoing commitment shares. During 2020, the Company sold 10,179,676 2021 , the Company sold an additional 2,750,000 shares of its common stock under the Purchase Agreement, resulting in aggregate proceeds of approximately $6.9 million to the Company. The Company expects to use the proceeds from this agreement for general corporate purposes and working capital. On March 11, 2021, the Company terminated the Purchase Agreement and, accordingly, the Company will not sell any further shares of its common stock to Lincoln Park under the Purchase Agreement. Settlement of Accrued Bonus In January 2021, the Company issued 165,413 shares of its common stock as payment for certain executive incentive bonuses accrued in 2020. Settlement of Lease Liability On September 27, 2021, the Company agreed to issue 200,000 shares of its common stock in connection with the lease termination related to its former headquarters located in Basking Ridge, NJ. As of September 30, 2021, these shares were not issued (see Note 8).

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Net Loss Per Share	Note 12 Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding adjusted to give effect to potentially dilutive securities. Restricted stock and unit awards, stock options, and warrants have not been included in the diluted loss per share calculation as their inclusion would have had an anti-dilutive effect. The potential common stock equivalents that have been excluded from the computation of diluted loss per share consist of the following: Nine months ended September 30, 2021 2020 Outstanding stock options 5,131,263 3,693,943 Nonvested restricted stock and unit awards 1,153,364 1,230,651 Stock purchase warrants 216,944 715,199 6,501,571 5,639,793 The following table presents a summary of stock purchase warrants outstanding at September 30, 2021: Number of Warrants Exercise Price Expiration Date 22,253 $ 5.68 3/30/2022 17,066 $ 12.60 6/30/2022 151,364 $ 12.60 8/18/2022 14,286 $ 12.60 8/31/2022 11,975 $ 15.30 12/22/2025 216,944 During the nine months ended September 30, 2021, a total of 498,255 warrants expired. The exercise price of these warrants ranged between $8.86 and $12.60.

Stock Based Compensation

Stock Based Compensation	9 Months Ended
	Sep. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Based Compensation	Note 13 . Stock Based Compensation The following table presents a summary of activity related to stock options during the nine months ended September 30, 2021: Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding, January 1, 2021 3,815,585 $ 5.56 8.9 $ 342,551 Granted 1,345,136 1.97 21,600 Exercised — — — Cancelled (29,458 ) 5.22 * Outstanding, September 30, 2021 5,131,263 $ 4.62 8.2 $ 73,800 Exercisable, September 30, 2021 1,988,192 $ 7.67 7.6 $ 36,000 * de minimis The intrinsic value is calculated as the difference between the fair market value at and the exercise price per share of the stock options. The options granted to employees generally vest over a four The following table presents a summary of activity related to restricted stock awards (“RSAs”) granted during the nine months ended September 30, 2021: Number of Shares Weighted Average Grant Date Fair Value Nonvested, January 1, 2021 25,645 $ 10.07 Granted 165,413 2.41 Vested (149,894 ) 2.82 Cancelled (5,687 ) 6.38 Nonvested, September 30, 2021 35,477 $ 2.82 In general, RSAs granted to employees vest over a four The following table presents a summary of activity related to restricted and deferred stock units (“Stock Units”) granted during the nine months ended : Number of Shares Weighted Average Grant Date Fair Value Nonvested, January 1, 2021 1,014,123 $ 1.50 Granted 438,316 2.07 Vested (329,198 ) 1.67 Cancelled (5,354 ) 1.97 Nonvested, September 30, 2021 1,117,887 $ 1.67 In general, Stock Units granted to employees vest over two four Immediately following the Company’s annual meeting of stockholders, the Company generally grants each non-employee director an equity award that vests over a 12-month period. Upon a non-employee director’s initial appointment or election to the board of directors, the Company grants such non-employee director an equity award subject to vesting as determined by the board of directors. The Company recognized stock compensation expense for its equity awards as follows: Three months ended September 30, Nine months ended September 30, 2021 2020 2021 2020 Selling, general and administrative $ 658,314 $ 541,757 $ 2,171,122 $ 1,789,122 Research and development 87,222 179,664 314,710 649,485 Cost of goods sold 14,901 21,507 54,761 51,944 Total expense $ 760,437 $ 742,928 $ 2,540,593 $ 2,490,551 Total unrecognized compensation cost related to unvested awards as of was $5.1 million and is expected to be recognized over the next 2.2 years. Valuation Information for Stock-Based Compensation The fair value of each stock option award during the three and nine months ended and 2020 was estimated on the date of grant using the Black-Scholes model. For the nine months ended September 30, 2021, expected volatility was based on historical common stock volatility of the Company’s peers xpected volatility for the nine months ended September 30, 2020, was based on historical volatility of the Company’s common stock. The weighted average assumptions used in the Black-Scholes option pricing model in valuing stock options granted in the three and nine months ended September 30, 2021 and 2020 are summarized in the table below. Nine months ended September 30, 2021 2020 Fair value at grant date $ 1.33 $ 0.98 Expected volatility 80.2 % 142.1 % Risk-free interest rate 0.7 % 0.7 % Expected holding period, in years 6.0 6.1 Dividend yield — % — %

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Note 14 . Income Taxes The Company may be eligible, from time to time, to receive cash from the sale of its net operating losses and research and development tax credits under New Jersey's Department of the Treasury - Division of Taxation NOL Transfer Program. On June 7, 2021, the Company received a net cash amount of approximately $ 1.4 and tax credits and recorded a tax benefit of approximately $880,000 in connection with this receipt. On September 22, 2021, the Company received notification from the New Jersey's Department of the Treasury - Division of Taxation requesting the return of an overpayment of roximately $549,000 T On May 6, 2020, the Company received a net cash amount of approximately 1.2 sale of its New Jersey state net operating losses and research and development tax credits related to the year ended December 31, 2018

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 15. Commitments and Contingencies Stockholders Litigation On July 8, 2019 and August 1, 2019, purported stockholders of the Company served putative class action lawsuits in the Superior Court of New Jersey for Somerset County, captioned Paul Kuehl vs. electroCore, Inc., et al. Shirley Stone vs. electroCore, Inc., et al. Kuehl Stone On October 31, 2019, the Company and the other defendants filed a motion to dismiss the complaint or in the alternative to stay the action in favor of the pending federal action (discussed below). On February 21, 2020, the court granted the defendants’ motion to dismiss the consolidated amended complaint with prejudice. On March 2, 2020 the court entered an amended order dismissing the consolidated amended complaint with prejudice. On March 27, 2020, the plaintiffs filed a notice of appeal with the N.J. Superior Court – Appellate Division. The appeal was argued on September 27, 2021. On October 8, 2021, the Appellate Division issued an order reversing the decision of the Superior Court. The case has been remanded to the Superior Court for oral argument on the motion to dismiss or the alternative stay. On September 26, 2019 and October 31, 2019, purported stockholders of the Company served putative class action lawsuits in the United States District Court for the District of New Jersey captioned Allyn Turnofsky vs. electroCore, Inc., et al. Priewe vs. electroCore, Inc., et al. In the Turnofsky Turnofsky A session with the JAMS mediator occurred on March 30, 2021. The Priewe On March 4, 2021, purported stockholder Richard Maltz brought a purported stockholder derivative action in the United States District Court for the District of New Jersey. The action is captioned Richard Maltz, derivatively on behalf of electroCore, Inc., vs. Francis R. Amato, et al. Turnofsky On March 8, 2021, purported stockholder Erin Yuson brought a purported stockholder derivative action in the United States District Court for the District of New Jersey. The action is captioned Erwin Yuson, derivatively on behalf of electroCore, Inc., vs. Francis R. Amato, et al. The plaintiffs in the Maltz Yuson Turnofsky The Company intends to continue to vigorously defend itself in these matters. However, in light of, among other things, the preliminary stage of these litigation matters, the Company is unable to determine the reasonable probability of loss or a range of potential loss. Accordingly, the Company has not established an accrual for potential losses, if any, that could result from any unfavorable outcome, and there can be no assurance that these litigation matters will not result in substantial defense costs and/or judgments or settlements that could adversely affect the Company’s financial condition. The Company expenses associated legal fees in the period they are incurred.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	(a) Basis of Presentation The accompanying condensed consolidated financial statements were prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) and with instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934, as amended. In the opinion of management, the Company has made all necessary adjustments, which include normal recurring adjustments necessary for a fair presentation of the Company’s condensed consolidated financial position and results of operations for the interim periods presented. Certain information and disclosures normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes for the year ended included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 11, 2021 . The results for the three and nine months ended September 30, 2021 are not necessarily indicative of the results to be expected for a full year, any other interim periods or any future year or period.
Principles of Consolidation	(b) Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of electroCore and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	(c) Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include allowances for doubtful accounts, trade credits, rebates, co-payment assistance and sales returns, valuation of inventory , stock compensation, and contingencies.
Reclass of Statement of Cash Flows Activity	(d) Revision of Statement of Cash Flows Activity In preparation of its financial statements for the quarter ended March 31, 2021, the Company realized that proceeds from its July 1, 2020 Commercial Insurance Premium Finance and Security Agreement should have been treated as a noncash activity instead of grossed up on the accompanying condensed consolidated statement of cash flows. Even though the amount was not considered material, the financial statements have been revised. As a result, cash used in operating and cash provided by financing activities for the nine months ended September 30, 2020, decreased by approximately $600,000. (e) Reclassification of Statement of Cash Flows Activity Certain prior period amounts have been reclassified to conform to current period presentation. The reclassifications did not have an impact on net loss as previously reported.

Significant Risks and Uncerta_2

Significant Risks and Uncertainties (Tables)	9 Months Ended
	Sep. 30, 2021
Risks And Uncertainties [Abstract]
Schedule of revenue channels accounted for 10% or more of the Company's net sales	Three months ended September 30, Nine months ended September 30, 2021 2020 2021 2020 Revenue channel: Department of Veterans Affairs and Department of Defense 63.6 59.8 60.7 59.0 National Health Service 24.1 24.2 25.6% 28.1%

Revenue Recognition (Tables)

Revenue Recognition (Tables)	9 Months Ended
	Sep. 30, 2021
Revenue From Contract With Customer [Abstract]
Summary of net sales disaggregated by geographic area	Three months ended September 30, Nine months ended September 30, 2021 2020 2021 2020 Geographic Market United States $ 1,103,604 $ 800,767 $ 2,810,152 $ 1,759,477 United Kingdom 366,966 278,340 1,037,908 801,055 Other 16,523 1,734 112,341 7,035 Total Net Sales $ 1,487,093 $ 1,080,841 $ 3,960,401 $ 2,567,567

Cash, Cash Equivalents and Ma_2

Cash, Cash Equivalents and Marketable Securities (Tables)	9 Months Ended
	Sep. 30, 2021
Investments Debt And Equity Securities [Abstract]
Schedule of cash, cash equivalents and marketable securities	As of Amortized Cost Unrealized Gain Unrealized (Loss) Fair Value Cash and cash equivalents $ 37,995,008 $ — $ — $ 37,995,008 Marketable securities: U.S. Treasury Bonds 1,001,506 — (426 ) 1,001,080 Total cash, cash equivalents, and marketable securities $ 38,996,514 $ — $ (426 ) $ 38,996,088 A s of December 31, 2020 Amortized Cost Unrealized Gain Unrealized (Loss) Fair Value Cash and cash equivalents $ 4,241,937 $ — $ — $ 4,241,937 Marketable securities: U.S. Treasury Bonds 18,388,970 — (2,810 ) 18,386,160 Total cash, cash equivalents, and marketable securities $ 22,630,907 $ — $ (2,810 ) $ 22,628,097

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Schedule of assets and liabilities carried at fair value	Fair Value Hierarchy September 30, 2021 Total Level 1 Level 2 Level 3 Assets Cash and cash equivalents $ 37,995,008 $ 37,995,008 $ — $ — Marketable Securities: U.S. treasury bonds 1,001,080 1,001,080 — — Total $ 38,996,088 $ 38,996,088 $ — $ — Fair Value Hierarchy December 31, 2020 Total Level 1 Level 2 Level 3 Assets Cash and cash equivalents $ 4,241,937 $ 4,241,937 $ — $ — Marketable Securities: U.S. treasury bonds 18,386,160 18,386,160 — — Total $ 22,628,097 $ 22,628,097 $ — $ —

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2021
Inventory Disclosure [Abstract]
Schedule of inventories stated at lower of cost or market	September 30, 2021 December 31, 2020 Raw materials $ 820,227 $ 1,008,653 Work in process 4,163,251 4,304,415 Finished goods 447,856 428,549 Total inventories, net 5,431,334 5,741,617 Less: noncurrent inventories 4,349,009 4,865,181 Current inventories, net $ 1,082,325 $ 876,436

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2021
Leases [Abstract]
Supplemental Balance Sheet Information for Operating Leases	September 30, 2021 December 31, 2020 Operating leases: Operating lease right of use assets $ 539,728 $ 517,257 Operating lease liabilities: Current portion of operating lease liabilities 58,482 534,547 Noncurrent operating lease liabilities 715,530 885,333 Total operating lease liabilities $ 774,012 $ 1,419,880 Weighted average remaining lease term (in years) 7.3 5.7 Weighted average discount rate 13.8 % 13.8 %
Future Minimum Lease Payments under Non-Cancellable Operating Leases	Remainder of 2021 $ 39,414 2022 160,486 2023 163,962 2024 167,524 2025 and thereafter 704,900 Total future minimum lease payments 1,236,286 Less: Amounts representing interest (462,274 ) Total $ 774,012

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2021
Payables And Accruals [Abstract]
Schedule of Accrued Expenses	September 30, 2021 December 31, 2020 Accrued professional fees $ 166,050 $ 270,543 Accrued bonuses 1,400,403 1,424,878 Accrued insurance expense 873,592 164,832 Other employee related expenses 425,067 371,033 Accrued state taxes 548,705 — Lease settlement liability 320,000 — Other 696,026 734,416 $ 4,429,843 $ 2,965,702

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Schedule of Common Stock Equivalents Excluded from Computation of Diluted Loss per Share	Nine months ended September 30, 2021 2020 Outstanding stock options 5,131,263 3,693,943 Nonvested restricted stock and unit awards 1,153,364 1,230,651 Stock purchase warrants 216,944 715,199 6,501,571 5,639,793
Schedule of stock purchase warrants outstanding	Number of Warrants Exercise Price Expiration Date 22,253 $ 5.68 3/30/2022 17,066 $ 12.60 6/30/2022 151,364 $ 12.60 8/18/2022 14,286 $ 12.60 8/31/2022 11,975 $ 15.30 12/22/2025 216,944

Stock Based Compensation (Table

Stock Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Activity Related to Stock Options	Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding, January 1, 2021 3,815,585 $ 5.56 8.9 $ 342,551 Granted 1,345,136 1.97 21,600 Exercised — — — Cancelled (29,458 ) 5.22 * Outstanding, September 30, 2021 5,131,263 $ 4.62 8.2 $ 73,800 Exercisable, September 30, 2021 1,988,192 $ 7.67 7.6 $ 36,000
Summary of Activity Related to Restricted Stock Awards Granted	Number of Shares Weighted Average Grant Date Fair Value Nonvested, January 1, 2021 25,645 $ 10.07 Granted 165,413 2.41 Vested (149,894 ) 2.82 Cancelled (5,687 ) 6.38 Nonvested, September 30, 2021 35,477 $ 2.82
Summary of Activity Related to Restricted Stock and Deferred Stock Units Granted	Number of Shares Weighted Average Grant Date Fair Value Nonvested, January 1, 2021 1,014,123 $ 1.50 Granted 438,316 2.07 Vested (329,198 ) 1.67 Cancelled (5,354 ) 1.97 Nonvested, September 30, 2021 1,117,887 $ 1.67
Schedule of Recognized Stock Compensation for Equity Awards	Three months ended September 30, Nine months ended September 30, 2021 2020 2021 2020 Selling, general and administrative $ 658,314 $ 541,757 $ 2,171,122 $ 1,789,122 Research and development 87,222 179,664 314,710 649,485 Cost of goods sold 14,901 21,507 54,761 51,944 Total expense $ 760,437 $ 742,928 $ 2,540,593 $ 2,490,551
Summary of Weighted Average Assumptions Used in Valuing Plans	Nine months ended September 30, 2021 2020 Fair value at grant date $ 1.33 $ 0.98 Expected volatility 80.2 % 142.1 % Risk-free interest rate 0.7 % 0.7 % Expected holding period, in years 6.0 6.1 Dividend yield — % — %

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2021
Commitments And Contingencies Disclosure [Abstract]
Schedule of stock purchase warrants outstanding	Number of Warrants Exercise Price Expiration Date 22,253 $ 5.68 3/30/2022 17,066 $ 12.60 6/30/2022 151,364 $ 12.60 8/18/2022 14,286 $ 12.60 8/31/2022 11,975 $ 15.30 12/22/2025 216,944

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details)	9 Months Ended
	Sep. 30, 2021USD ($)
Accounting Policies [Abstract]
Decrease in operating lease liabilities	$ (600,000)

Significant Risks and Uncerta_3

Significant Risks and Uncertainties - Additional Information (Details) $ in Millions	Jun. 07, 2021USD ($)	May 06, 2020USD ($)	Sep. 30, 2021USD ($)facility	Sep. 30, 2020facility	Sep. 30, 2021USD ($)facility	Sep. 30, 2020USD ($)facility
Risks And Uncertainties [Line Items]
Sale of net operating losses	$ 1.4	$ 1.2
Incurred loss					$ 12.3	$ 17.2
Cash, cash equivalents and marketable securities			$ 39		39
Net proceeds from sale receivable					$ 25.7
Channel One [Member] | VA/DoD facilities
Risks And Uncertainties [Line Items]
Number of channels | facility					4	3
Channel One [Member] | VA/DoD facilities | Net Sales
Risks And Uncertainties [Line Items]
Number of channels | facility			4	5
Channel One [Member] | VA/DoD facilities | Net Sales | Revenue from Rights Concentration Risk
Risks And Uncertainties [Line Items]
Percentage of net sales			53.90%	58.60%	52.10%	41.00%
Channel Two [Member] | Net Sales | Revenue from Rights Concentration Risk
Risks And Uncertainties [Line Items]
Percentage of net sales					10.00%
Channel Two [Member] | VA/DoD facilities | Net Sales
Risks And Uncertainties [Line Items]
Number of channels | facility			2		2
Channel Two [Member] | VA/DoD facilities | Net Sales | Revenue from Rights Concentration Risk
Risks And Uncertainties [Line Items]
Percentage of net sales			10.00%
Channel Two [Member] | VA/DoD facilities | Minimum | Net Sales | Revenue from Rights Concentration Risk
Risks And Uncertainties [Line Items]
Percentage of net sales					10.00%

Significant Risks and Uncerta_4

Significant Risks and Uncertainties - Schedule of company's net sales (Details) - Net Sales - Revenue from Rights Concentration Risk	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Department of Veterans Affairs and Department of Defense [Member]
Concentration Risk [Line Items]
Revenue, percentage	63.60%	59.80%	60.70%	59.00%
National Health Service [Member]
Concentration Risk [Line Items]
Revenue, percentage	24.10%	24.20%	25.60%	28.10%

Revenue Recognition - Summary o

Revenue Recognition - Summary of Net Sales Disaggregated by Geographic Area (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Disaggregation Of Revenue [Line Items]
Total Net Sales	$ 1,487,093	$ 1,080,841	$ 3,960,401	$ 2,567,567
United States
Disaggregation Of Revenue [Line Items]
Total Net Sales	1,103,604	800,767	2,810,152	1,759,477
United Kingdom
Disaggregation Of Revenue [Line Items]
Total Net Sales	366,966	278,340	1,037,908	801,055
Other
Disaggregation Of Revenue [Line Items]
Total Net Sales	$ 16,523	$ 1,734	$ 112,341	$ 7,035

Revenue Recognition - Additiona

Revenue Recognition - Additional Information (Details)	Sep. 30, 2021USD ($)
Revenue From Contract With Customer [Abstract]
Maximum amount of reduction in monthly co-payments of each prescription	$ 100

Cash, Cash Equivalents, and Mar

Cash, Cash Equivalents, and Marketable Securities - Summary of Cash, Cash Equivalents, and Marketable Securities (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Schedule Of Available For Sale Securities [Line Items]
Cash and Cash Equivalents, Amortized Cost	$ 37,995,008	$ 4,241,937
Cash and Cash Equivalents, Unrealized Gain
Cash and Cash Equivalents, Unrealized (Loss)
Cash and cash equivalents	37,995,008	4,241,937
Marketable securities, Fair Value	1,001,080	18,386,160
Cash, cash equivalents and marketable securities, Amortized Cost	38,996,514	22,630,907
Cash, cash equivalents and marketable securities, Unrealized Gain
Cash, cash equivalents, and marketable securities, Unrealized (Loss)	(426)	(2,810)
Cash, cash equivalents, and marketable securities, Fair Value	38,996,088	22,628,097
U.S. Treasury Bonds
Schedule Of Available For Sale Securities [Line Items]
Marketable securities, Amortized Cost	1,001,506	18,388,970
Marketable securities, Unrealised Gain
Marketable securities, Unrealized (Loss)	(426)	(2,810)
Marketable securities, Fair Value	1,001,080	18,386,160
Cash, cash equivalents, and marketable securities, Fair Value	$ 1,001,080	$ 18,386,160

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Assets and Liabilities Carried at Fair Value (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 37,995,008	$ 4,241,937
Marketable Securities	38,996,088	22,628,097
U.S. Treasury Bonds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable Securities	1,001,080	18,386,160
(Level 1)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents	37,995,008	4,241,937
Marketable Securities	38,996,088	22,628,097
(Level 1) | U.S. Treasury Bonds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable Securities	1,001,080	18,386,160
(Level 2)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents
Marketable Securities
(Level 2) | U.S. Treasury Bonds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable Securities
(Level 3)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents
Marketable Securities
(Level 3) | U.S. Treasury Bonds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable Securities

Inventories - Inventories (Deta

Inventories - Inventories (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Raw materials	$ 820,227	$ 1,008,653
Work in process	4,163,251	4,304,415
Finished goods	447,856	428,549
Total inventories, net	5,431,334	5,741,617
Less: noncurrent inventories	4,349,009	4,865,181
Current inventories, net	$ 1,082,325	$ 876,436

Inventories - Additional Inform

Inventories - Additional Information (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Inventory [Line Items]
Noncurrent inventory raw materials	$ 1,100,000	$ 700,000
Noncurrent inventory work in process	3,200,000	4,200,000
Inventory Valuation and Obsolescence [Member]
Inventory [Line Items]
Reserves for obsolete inventory	$ 760,940	$ 721,462

Leases - Supplemental Balance S

Leases - Supplemental Balance Sheet Information for Operating Leases (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Operating leases:
Operating lease right of use assets	$ 539,728	$ 517,257
Current portion of operating lease liabilities	58,482	534,547
Noncurrent operating lease liabilities	715,530	885,333
Total operating lease liabilities	$ 774,012	$ 1,419,880
Weighted average remaining lease term (in years)	7 years 3 months 18 days	5 years 8 months 12 days
Weighted average discount rate	13.80%	13.80%

Leases - Future Minimum Lease P

Leases - Future Minimum Lease Payments under Non-Cancellable Operating Leases (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Leases [Abstract]
Remainder of 2021	$ 39,414
2022	160,486
2023	163,962
2024	167,524
2025 and thereafter	704,900
Total future minimum lease payments	1,236,286
Less: Amounts representing interest	(462,274)
Total	$ 774,012	$ 1,419,880

Leases - Additional Information

Leases - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Oct. 05, 2021	Oct. 04, 2021	Sep. 27, 2021
Lessor, Lease, Description [Line Items]
Recognized lease expenses	$ 52,351	$ 149,731	$ 139,597	$ 422,765
Cash	398,523		398,523				$ 500,000
Accrued lessor amount	$ 320,000		$ 320,000
Shares issued							200,000
Lessor [Member] | Subsequent Event [Member]
Lessor, Lease, Description [Line Items]
Cash					$ 101,477
Shares issued						200,000

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Accrued Liabilities Current [Abstract]
Accrued professional fees	$ 166,050	$ 270,543
Accrued bonuses	1,400,403	1,424,878
Accrued insurance expense	873,592	164,832
Other employee related expenses	425,067	371,033
Accrued state taxes	548,705
Lease settlement liability	320,000
Other	696,026	734,416
Accrued expenses	$ 4,429,843	$ 2,965,702

Accrued Expenses and Other Cu_4

Accrued Expenses and Other Current Liabilities (Details) - USD ($)	Jul. 02, 2021	Jul. 02, 2020	Sep. 30, 2021	Sep. 30, 2020	Jul. 31, 2021
Accrued Expenses and Other Current Liabilities [Line Item]
Proceeds from borrowings				$ 1,410,524
Interest expense			2,646
Remaining balance of notes payable			$ 873,592
Finance and Security Agreement
Accrued Expenses and Other Current Liabilities [Line Item]
Proceeds from borrowings	$ 1,200,000	$ 1,200,000
Interest rate on the Loan	1.55%	2.18%
Monthly installments payable					$ 124,800

Notes Payable - Additional Info

Notes Payable - Additional Information (Details) - USD ($)	May 04, 2020	Sep. 30, 2021	Sep. 30, 2020
Notes Payable [Line Items]
Proceeds from borrowings			$ 1,410,524
Promissory Note | Citibank, N.A. | Paycheck Protection Program
Notes Payable [Line Items]
Proceeds from borrowings	$ 1,400,000

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Details) - USD ($)	Jul. 02, 2021	Aug. 30, 2021	Mar. 27, 2020	Sep. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Sep. 30, 2021	Dec. 31, 2020	Sep. 27, 2021
Stock Purchase Agreement [Line Items]
Net proceeds of offering amount	$ 18.8
Common stock, shares issued				70,442,309				70,442,309	45,559,765
Settlement of accrued bonus, shares								1,345,136
Common Stock
Stock Purchase Agreement [Line Items]
Issuance of stock, Shares	20,700,000	952,380		20,700,000	2,750,000	6,079,676	8,028,372
purchase per share value	$ 1	$ 1.05
Common stock, shares issued										200,000
Shares issued. price per share	$ 1	$ 1.05
Settlement of accrued bonus, shares								165,413
Lincoln Park
Stock Purchase Agreement [Line Items]
Proceeds from shares issued			$ 25,000,000
Stock Purchase Agreement | Lincoln Park
Stock Purchase Agreement [Line Items]
Issuance of stock, Shares								2,750,000	10,179,676
Value of shares issued			$ 5,000,000
Common stock, shares issued			461,676
Fair value of common stock shares issued			$ 186,300
Additional commitment shares issued			230,838
Proceeds from shares issued								$ 6,900,000	$ 15,500,000

Net Loss Per Share - Additional

Net Loss Per Share - Additional Information (Details)	9 Months Ended
	Sep. 30, 2021USD ($)$ / shares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Warrants expired | $	$ 498,255
Minimum
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price	$ 8.86
Maximum
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price	$ 12.60

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Common Stock Equivalents Excluded from Computation of Diluted Loss per Share (Details) - shares	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	6,501,571	5,639,793
Outstanding stock options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	5,131,263	3,693,943
Nonvested restricted stock and unit awards
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	1,153,364	1,230,651
Stock purchase warrants
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	216,944	715,199

Net Loss Per Share - Schedule_2

Net Loss Per Share - Schedule of stock purchase warrants outstanding (Details 2)	9 Months Ended
	Sep. 30, 2021USD ($)$ / shares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Warrants	$ 216,944,000
Exercise Price 5.68 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Warrants	$ 22,253
Exercise Price | $ / shares	$ 5.68
Expiration Date	Mar. 30, 2022
Exercise Price 12.60 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Warrants	$ 17,066
Exercise Price | $ / shares	$ 12.60
Expiration Date	Jun. 30, 2022
Exercise Price 12.60 One [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Warrants	$ 151,364
Exercise Price | $ / shares	$ 12.60
Expiration Date	Aug. 18, 2022
Exercise Price 12.60 Two [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Warrants	$ 14,286
Exercise Price | $ / shares	$ 12.60
Expiration Date	Aug. 31, 2022
Exercise Price 12.60 Three [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Warrants	$ 11,975
Exercise Price | $ / shares	$ 15.30
Expiration Date	Dec. 22, 2025

Stock Based Compensation - Addi

Stock Based Compensation - Additional Information (Details) $ in Millions	9 Months Ended
	Sep. 30, 2021USD ($)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	4 years
Unrecognized compensation cost related to unvested awards	$ 5.1
Unrecognized compensation expected to be recognized	2 years 2 months 12 days
RSAs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	4 years
Stock Units | Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	2 years
Stock Units | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	4 years

Stock Based Compensation - Summ

Stock Based Compensation - Summary of Activity Related to Stock Options (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Number of Options
Number of Options, Outstanding, January 1, 2021	3,815,585
Number of Options, Granted	1,345,136
Number of Options, Exercised
Number of Options, Cancelled	(29,458)
Number of Options, Outstanding, September 30, 2021	5,131,263	3,815,585
Number of Options, Exercisable, September 30, 2021	1,988,192
Weighted Average Exercise Price
Weighted Average Exercise Price, Outstanding, January 1, 2021	$ 5.56
Weighted Average Exercise Price, Granted	1.97
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Cancelled	5.22
Weighted Average Exercise Price, Outstanding, September 30, 2021	4.62	$ 5.56
Weighted Average Exercise Price, Exercisable, September 30, 2021	$ 7.67
Weighted Average Remaining Contractual Term (Years), Outstanding, January 1, 2021	8 years 2 months 12 days	8 years 10 months 24 days
Weighted Average Remaining Contractual Term (Years), Exercisable, September 30, 2021	7 years 7 months 6 days
Aggregate Intrinsic Value, Outstanding, January 1, 2021	$ 73,800	$ 342,551
Aggregate Intrinsic Value, Granted	21,600
Aggregate Intrinsic Value, Exercised
Aggregate Intrinsic Value, Exercisable, September 30, 2021	$ 36,000

Stock Based Compensation - Su_2

Stock Based Compensation - Summary of Activity Related to Restricted Stock Awards Granted (Details)	9 Months Ended
	Sep. 30, 2021$ / sharesshares
RSAs
Number of Shares
Number of Shares, Nonvested, January 1,2021 | shares	25,645
Number of Shares, Granted | shares	165,413
Number of Shares, Vested | shares	(149,894)
Number of Shares, Cancelled | shares	(5,687)
Number of Shares, Nonvested, September 30, 2021 | shares	35,477
Weighted Average Grant Date Fair Value
Weighted Average Grand Date Fair Value, Nonvested, January 1, 2021 | $ / shares	$ 10.07
Weighted Average Grand Date Fair Value, Granted | $ / shares	2.41
Weighted Average Grand Date Fair Value, Vested | $ / shares	2.82
Weighted Average Grand Date Fair Value, Cancelled | $ / shares	6.38
Weighted Average Grand Date Fair Value, Nonvested, September 30, 2021 | $ / shares	$ 2.82
Restricted Stock And Deferred Stock [Member]
Number of Shares
Number of Shares, Nonvested, January 1,2021 | shares	1,014,123
Number of Shares, Granted | shares	438,316
Number of Shares, Vested | shares	(329,198)
Number of Shares, Cancelled | shares	(5,354)
Number of Shares, Nonvested, September 30, 2021 | shares	1,117,887
Weighted Average Grant Date Fair Value
Weighted Average Grand Date Fair Value, Nonvested, January 1, 2021 | $ / shares	$ 1.50
Weighted Average Grand Date Fair Value, Granted | $ / shares	2.07
Weighted Average Grand Date Fair Value, Vested | $ / shares	1.67
Weighted Average Grand Date Fair Value, Cancelled | $ / shares	1.97
Weighted Average Grand Date Fair Value, Nonvested, September 30, 2021 | $ / shares	$ 1.67

Stock Based Compensation - Su_3

Stock Based Compensation - Summary of Activity Related to Restricted Stock and Deferred Stock Units Granted (Details) - Stock Units	9 Months Ended
	Sep. 30, 2021$ / sharesshares
Number of Shares
Number of Shares, Nonvested, January 1,2021 | shares	1,014,123
Number of Shares, Granted | shares	438,316
Number of Shares, Vested | shares	(329,198)
Number of Shares, Cancelled | shares	(5,354)
Number of Shares, Nonvested, September 30, 2021 | shares	1,117,887
Weighted Average Grant Date Fair Value
Weighted Average Grand Date Fair Value, Nonvested, January 1, 2021 | $ / shares	$ 1.50
Weighted Average Grand Date Fair Value, Granted | $ / shares	2.07
Weighted Average Grand Date Fair Value, Vested | $ / shares	1.67
Weighted Average Grand Date Fair Value, Cancelled | $ / shares	1.97
Weighted Average Grand Date Fair Value, Nonvested, September 30, 2021 | $ / shares	$ 1.67

Stock Based Compensation - Sche

Stock Based Compensation - Schedule of Recognized Stock Compensation for Equity Awards (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation	$ 760,437	$ 742,928	$ 2,540,593	$ 2,490,551
Selling, General and Administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation	658,314	541,757	2,171,122	1,789,122
Research and Development
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation	87,222	179,664	314,710	649,485
Cost of Goods Sold
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation	$ 14,901	$ 21,507	$ 54,761	$ 51,944

Stock Based Compensation - Su_4

Stock Based Compensation - Summary of Weighted Average Assumptions Used in Valuing Plans (Details) - $ / shares	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Fair value at grant date	$ 1.33	$ 0.98
Expected volatility	80.20%	142.10%
Risk-free interest rate	0.70%	0.70%
Expected holding period, in years	6 years	6 years 1 month 6 days
Dividend yield

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	Jun. 07, 2021	May 06, 2020	Sep. 22, 2021
Operating Loss Carryforwards [Line Items]
Net cash from sale of New Jersey state net operating losses	$ 1,400,000	$ 1,200,000
Income tax return of overpayment			$ 549,000
Tax benefit	$ 880,000,000,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details)	Jul. 17, 2020
Class Of Warrant Or Right [Line Items]
Number of investors as defendants	2